Long-term treatment with infliximab in inflammatory bowel disease: Safety and tolerability issues

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 617-632

  Caviglia, Renato ^a   Boškoski, Ivo ^a   Cicala, Michele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Crohn's disease; Infections; Inflammatory bowel disease; Infliximab; Malignancy; Safety; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BCG VACCINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NARCOTIC ANALGESIC AGENT; ONERCEPT; PLACEBO; SEMAPIMOD; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABDOMINAL SURGERY; AGITATION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANAPHYLAXIS; APATHY; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BACTERIAL INFECTION; BRADYCARDIA; BREAST CANCER; BRONCHITIS; BRONCHOSPASM; CANDIDIASIS; CARDIOVASCULAR DISEASE; CELLULITIS; CHEILITIS; CHILL; CHOLECYSTITIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COGNITIVE DEFECT; COMPLEMENT BLOOD LEVEL; COMPLEX FORMATION; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; CROHN DISEASE; CYANOSIS; DEMYELINATING DISEASE; DEPRESSION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DIVERTICULITIS; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DRY SKIN; DYSESTHESIA; DYSPEPSIA; DYSPNEA; ECCHYMOSIS; ECZEMA; EDEMA; ENDOPHTHALMITIS; ENTERITIS; EPISTAXIS; EYE CANCER; EYE DISEASE; FATIGUE; FLUSHING; FURUNCULOSIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GENITAL TRACT CANCER; GRANULOMATOUS INFLAMMATION; HEALING IMPAIRMENT; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEMATOMA; HEMIPARESIS; HEPATITIS; HEPATITIS B; HEPATOBILIARY SYSTEM CANCER; HERPES; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HOT FLUSH; HUMAN; HYPERKERATOSIS; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; IMMUNOMODULATION; INCONTINENCE; INFECTION; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; INTESTINE PERFORATION; INTESTINE STENOSIS; ISCHEMIA; KERATOCONJUNCTIVITIS; LISTERIOSIS; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; LUNG EDEMA; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MILIARY TUBERCULOSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; MYCOSIS; NAUSEA; NEOPLASM; NERVOUSNESS; NONHUMAN; ONYCHOMYCOSIS; OPPORTUNISTIC INFECTION; PAIN; PARESTHESIA; PATHOGENESIS; PERIORBITAL EDEMA; PERIPHERAL ISCHEMIA; PETECHIA; PLEURA EFFUSION; PLEURISY; PNEUMOCYSTOSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREGNANT WOMAN; PREVALENCE; PRURITUS; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; RECTUM CARCINOMA; REMISSION; RESPIRATORY TRACT ALLERGY; REVIEW; RIGOR; RISK BENEFIT ANALYSIS; RISK FACTOR; ROSACEA; SEBORRHEA; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN CANCER; SKIN PIGMENTATION; SOMNOLENCE; STEADY STATE; STEROID THERAPY; STRUCTURE ACTIVITY RELATION; SWEATING; SYNCOPE; T CELL LYMPHOMA; TACHYCARDIA; THORAX PAIN; THROMBOPHLEBITIS; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VAGINITIS; VASOSPASM; VERRUCA VULGARIS; VERTIGO; VESICULAR RASH; VIRUS INFECTION; VIRUS PNEUMONIA; VIRUS REACTIVATION; WALKING DIFFICULTY; WEAKNESS; DRUG ANTAGONISM; DRUG LABELING; METHODOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG LABELING; HUMANS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54449085378     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.617     Document Type: Review

References (83)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:1008-16
2. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2003;31:1-20
3. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
4. Schreiber S. Medical treatment: an overview. In: Satsangi J, Inflammatory bowel disease. Churchill Livingstone, London: Elsevier Limited; 2003. p. 297-301
5. Hanauer S, Sandborn WJ; and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
7. Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007;56:2-5
8. Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol 2005;42(8):42-9
9. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis Induced by T-bet deficiency in the innate immune system. Cell 2007;131:33-45
10. Hecht GA. Inflammatory bowel disease-live transmission. N Engl J Med 2008;358(5):528-30
11. Hanauer S. Efficacy and safety of tumour necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord 2004;4(Suppl 3):S18-24
12. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005;34(Suppl 1):12-8
13. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9
14. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-87
15. Nesbitt A, Fossati G, Bergin M, et ail Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumour necrosis factor alpha agents. Inflamm Bowel Dis 2007;13(11):1323-32
16. Reddy JG, Loftus E Jr. Safety of in fliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35(4):837-55
17. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46(8):645-60
18. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with antitumour necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125(1):32-9
19. Periodic Safety Update Reports. (PSUR 16, October 2007;PSUR 17, Apri1 2008)
20. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86
21. Dixon WG, Watson K, Lunt M, et al.; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54(8):2368-76
22. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31
23. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007;13(39):5238-44
24. Lichtenstein GR, Feagan BG, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
25. Colombel JF, D'Haens G, Rutgeerts P, et al. No new safety signals identified in Crohn's disease patients treated with infliximab in an interim review of the ENCORE registry. Gastroenterology 2008;134:A-472 [T1048]
26. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36
27. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007;13(7):896-902
28. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003;30:1624-5
29. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7
30. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5
31. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9
32. Ehlers S. Tumour necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41:S199-203
33. Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;169:4620-7
34. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during antitumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27(1):19-30
35. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
36. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7
37. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9
38. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
39. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of TB in rheumatoid arthritis associated with tumour necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92
40. Remicade (infliximab) for IV injection [prescribing information]. Malvern, PA. Centocor; 2006
41. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumour necrosis factor-alpha, California, 2002 - 2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6
42. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent TB infection. Can Med Assoc J 2003;168:1153-6
43. Vlachaki E, Psathakis K, Tsintiris K, et al. Delayed response to anti-TB treatment in a patient on infliximab. Respir Med 2005;99:648-52
44. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
45. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53
46. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
47. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
48. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during antitumour necrosis factor alpha therapy for inflammatory arthritides. Artkritis Rheum 2001;44(12):2862-9
49. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during antitumour necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004;10:28-31
50. Andersen N, Caspersen S, Peterse N. Crohn disease and demyelinating. The National Danish Crohn's colitis infliximab database 1999 - 2005. Gut 2006;55(Suppl V):A109
51. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-26
52. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multi-centre matched pair study. Gut 2006;55:228-33
53. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105(6):1716-23
54. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
55. Bernstein CN, Blanchard JE Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62
56. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-21
57. Gyde SN, Prior P, MacArtney JC, et al. Malignancy in Crohn's disease. Gut 1980;21:1024-9
58. LjungT, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53
59. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukaemia 2000;14:991-7
60. Belhadj K, Reyes F, Farcewt J-P, et al. Hepatosplenic T cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9
61. Cooke C, Krenacs L, Stelter-Stevenson M, et al. Hepatosplenic T cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta origin. Blood 1996;88:4265-74
62. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gamma delta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3
63. Mahadevan U. Continuing immunomodulators and biologic medications in pregnant IBD patients-pro. Inflamm Bowel Dis 2007;13(11):1439-40
64. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56(6):830-7
65. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133(4):1106-12
66. Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 2003;52(2):159-161
67. Remicade product information. In: Physicians desk reference. 58th edition. Montvale, NJ: Medical Economics Company; Inc.; 2004. p. 1145-8
68. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8
69. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10):1255-8
70. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99(12):2385-92
71. Mahadevan U, Kane SV, Church JA. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008;134(Suppl 1):A-69
72. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41
73. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumour necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303-12
74. Krown KA, Page MT, Nguyen C, et al. Tumour necrosis factor α-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65
75. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40
76. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Ann Intern Med 2003;138:807-11
77. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6
78. Foeldvari I, Kruger E, Schneider T. Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann Rheum Dis 2003;62:908-9
79. Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132(3):863-73
80. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405
81. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
82. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with antitumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9
83. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-11